Healthcare
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for serious diseases, primarily cystic fibrosis (CF). Its main products are a suite of CFTR modulators like TRIKAFTA/KAFTRIO, and it is expanding into other areas such as sickle cell disease, kidney disease, and pain management. Vertex holds a leading market position in CF treatments and is actively pursuing a pipeline of innovative therapies.
AI-generated summary. Not investment advice.